Effects of anti-IL-6 receptor antibody on human monocytes

被引:11
作者
Tono, Toshihiro [1 ]
Aihara, Satoko [1 ]
Hoshiyama, Takayuki [1 ]
Arinuma, Yoshiyuki [1 ]
Nagai, Tatsuo [1 ]
Hirohata, Shunsei [1 ]
机构
[1] Kitasato Univ, Sch Med, Dept Rheumatol & Infect Dis, Sagamihara, Kanagawa 2520374, Japan
关键词
Apoptosis; IL-6; Monocytes; Rheumatoid arthritis; Tocilizumab; RHEUMATOID-ARTHRITIS PATIENTS; MONOCLONAL-ANTIBODY; DOSE-ESCALATION; SYNOVIAL TISSUE; BLOOD MONOCYTES; PLASMA IL-6; TNF-ALPHA; INTERLEUKIN-6; INHIBITION; CYTOKINES;
D O I
10.3109/14397595.2014.914016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To explore the effects of anti-IL-6 receptor antibody, tocilizumab on function of human monocytes. Methods. Monocytes from healthy donors were cultured in the presence of staphylococcal enterotoxin B (SEB) with pharmacologically attainable concentrations of tocilizumab or control IgG. The expression of IL-6 mRNA was determined using quantitative RT-PCR. The expression of CD80 and CD86 and the induction of apoptosis of monocytes were measured using flow cytometry. Results. Tocilizumab promoted apoptosis of SEB-stimulated monocytes. The induction of apoptosis of monocytes by tocilizumab were reversed by addition of IgG, but not IgG F(ab')(2) fragments. Tocilizumab significantly suppressed the expression of CD80, but not that of CD86, on SEB-stimulated monocytes. Finally, tocilizumab significantly suppressed the expression of mRNA for IL-6 of monocytes stimulated with SEB. Conclusions. These results demonstrate that one of the mechanism of action of tocilizumab involves the induction of apoptosis of monocytes, which requires interaction with Fc receptor on monocytes. Moreover, the data also indicate that tocilizumab inhibit IL-6 production of monocytes at mRNA levels.
引用
收藏
页码:79 / 84
页数:6
相关论文
共 50 条
  • [1] Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy
    Snir, A.
    Kessel, A.
    Haj, T.
    Rosner, I.
    Slobodin, G.
    Toubi, E.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (04) : 697 - 700
  • [2] Anti-IL-6 receptor antibody does not ameliorate radiation pneumonia in mice
    Ogata, Toshiyuki
    Yamazaki, Hideya
    Teshima, Teruki
    Tsuchiya, Takahiro
    Nishimoto, Norihiro
    Matsuura, Nariaki
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2012, 4 (02) : 273 - 276
  • [3] Anti-IL-6 receptor monoclonal antibody as a new treatment of endometriosis
    El-Zayadi, Ahmed A.
    Mohamed, Sara A.
    Arafa, Mohammad
    Mohammed, Shereen M.
    Zayed, Abdelhady
    Abdelhafez, Mohamed S.
    Badawy, Ahmed M.
    IMMUNOLOGIC RESEARCH, 2020, 68 (06) : 389 - 397
  • [4] Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study
    Xu, Zhenhua
    Bouman-Thio, Esther
    Comisar, Craig
    Frederick, Bart
    Van Hartingsveldt, Bart
    Marini, Joseph C.
    Davis, Hugh M.
    Zhou, Honghui
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 72 (02) : 270 - 281
  • [5] Effects of Interleukin-6 (IL-6) and an Anti-IL-6 Monoclonal Antibody on Drug-Metabolizing Enzymes in Human Hepatocyte Culture
    Dickmann, Leslie J.
    Patel, Sonal K.
    Rock, Dan A.
    Wienkers, Larry C.
    Slatter, J. Greg
    DRUG METABOLISM AND DISPOSITION, 2011, 39 (08) : 1415 - 1422
  • [6] Therapeutic effects of an anti-IL-6 antibody in fungal keratitis: Macrophage inhibition and T cell subset regulation
    Peng, Lulu
    Zhong, Jing
    Xiao, Yichen
    Wang, Bowen
    Li, Saiqun
    Deng, Yuqing
    He, Dalian
    Yuan, Jin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 85
  • [7] Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis
    Miyagawa, Ippei
    Nakayamada, Shingo
    Saito, Kazuyoshi
    Hanami, Kentaro
    Nawata, Masao
    Sawamukai, Norifumi
    Nakano, Kazuhisa
    Yamaoka, Kunihiro
    Tanaka, Yoshiya
    MODERN RHEUMATOLOGY, 2014, 24 (03) : 405 - 409
  • [8] The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab
    Shima, Yoshihito
    Kuwahara, Yusuke
    Murota, Hiroyuki
    Kitaba, Shun
    Kawai, Mari
    Hirano, Toru
    Arimitsu, Junsuke
    Narazaki, Masashi
    Hagihara, Keisuke
    Ogata, Atsushi
    Katayama, Ichiro
    Kawase, Ichiro
    Kishimoto, Tadamitsu
    Tanaka, Toshio
    RHEUMATOLOGY, 2010, 49 (12) : 2408 - 2412
  • [9] The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis
    Ohsugi, Yoshiyuki
    Kishimoto, Tadamitsu
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (05) : 669 - 681
  • [10] Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica A pilot study
    Araki, Manabu
    Matsuoka, Takako
    Miyamoto, Katsuichi
    Kusunoki, Susumu
    Okamoto, Tomoko
    Murata, Miho
    Miyake, Sachiko
    Aranami, Toshimasa
    Yamamura, Takashi
    NEUROLOGY, 2014, 82 (15) : 1302 - 1306